Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Julie Cothren, DPh

Advertisement

Articles by Julie Cothren, DPh

It's Time to Get Serious About New Rules for Handling Hazardous Drugs

ByJulie Cothren, DPh
April 23rd 2019

Implementation of new standards for handling hazardous drugs in healthcare facilities is coming closer to reality now that the calendar has flipped to 2019.

Advertisement

Latest Updated Articles

  • It's Time to Get Serious About New Rules for Handling Hazardous Drugs
    It's Time to Get Serious About New Rules for Handling Hazardous Drugs

    April 23rd 2019



Advertisement
Advertisement

Trending on OncLive

1

Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS

2

Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML

3

ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML

4

Dr Gangat on Phase 2 Efficacy and Safety Data for DISC-3405 in Polycythemia Vera

5

Reassessing the Continuous-vs-Fixed-Duration Debate in Frontline Chronic Lymphocytic Leukemia

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us